If we can just push up a bit and move out of the .
Post# of 36537
(Total Views: 316)
Posted On: 07/23/2020 10:20:07 AM
If we can just push up a bit and move out of the .60's, that would be something.
This week, we have had pretty good volume, but have still been stuck in between .60 - .62. Today, the volume looks like it might be lighter than what it has been this week, so maybe we see a jump, with less volume, who know.
Anyways, BARDA seems to have no problem handing out funds to companies, so let's hope they see Generex as one of those companies worth funding as they have in place the total package to have a vaccine in place including manufacturing. Not sure what else is needed, when you compare to some of the others that have received funding overall.
Final thoughts on all of this. I'm still bewildered on what is taking the SEC so long to approve the GNBT S1. I'm still not sure why we haven't seen or heard anything on getting the S1 put in for NGIO as that should now be paramount for management to get them up and running on NASDAQ or wherever to make them a true force out there. Joe needs to be on top of all of this including working diligently with SEC to ensure all documents are put in correctly, all questions are answered on time, everything is done properly. There has been enough time that has gone by working on all of this with Generex and NGIO that there should not be any of these mistakes reoccurring anymore in SEC documents or PRs.
This week, we have had pretty good volume, but have still been stuck in between .60 - .62. Today, the volume looks like it might be lighter than what it has been this week, so maybe we see a jump, with less volume, who know.
Anyways, BARDA seems to have no problem handing out funds to companies, so let's hope they see Generex as one of those companies worth funding as they have in place the total package to have a vaccine in place including manufacturing. Not sure what else is needed, when you compare to some of the others that have received funding overall.
Final thoughts on all of this. I'm still bewildered on what is taking the SEC so long to approve the GNBT S1. I'm still not sure why we haven't seen or heard anything on getting the S1 put in for NGIO as that should now be paramount for management to get them up and running on NASDAQ or wherever to make them a true force out there. Joe needs to be on top of all of this including working diligently with SEC to ensure all documents are put in correctly, all questions are answered on time, everything is done properly. There has been enough time that has gone by working on all of this with Generex and NGIO that there should not be any of these mistakes reoccurring anymore in SEC documents or PRs.
(0)
(1)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼